Page last updated: 2024-10-22

acetaminophen and Hepatolenticular Degeneration

acetaminophen has been researched along with Hepatolenticular Degeneration in 6 studies

Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.

Hepatolenticular Degeneration: A rare autosomal recessive disease characterized by the deposition of copper in the BRAIN; LIVER; CORNEA; and other organs. It is caused by defects in the ATP7B gene encoding copper-transporting ATPase 2 (EC 3.6.3.4), also known as the Wilson disease protein. The overload of copper inevitably leads to progressive liver and neurological dysfunction such as LIVER CIRRHOSIS; TREMOR; ATAXIA and intellectual deterioration. Hepatic dysfunction may precede neurologic dysfunction by several years.

Research Excerpts

ExcerptRelevanceReference
" In Europe and North America a large proportion of cases are due to acetaminophen and to idiosyncratic drug reactions, whereas reports from emerging countries in Asia and Africa feature viral illnesses, particularly hepatitis B and E."4.84Etiologies of acute liver failure. ( Lee, WM, 2008)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Di Giorgio, A1
Nicastro, E1
Dalla Rosa, D1
Nebbia, G1
Sonzogni, A1
D'Antiga, L1
Rajaram, P1
Subramanian, R1
Olson, KR1
Davarpanah, AH1
Schaefer, EA1
Elias, N1
Misdraji, J1
Gandhi, H1
Davies, N1
Lee, WM1
Ryder, SD1
Beckingham, IJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690]Phase 247 participants (Actual)Interventional2012-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Ammonia

To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours

InterventionPercent Change (Mean)
Maximum Dose Level 3.33 g/24h41.2
Maximum Dose Level 6.65 g/24h16.6
Maximum Dose Level 10 g/24h41.8
Maximum Dose Level 20g/24h38.4

Measurement of OCR-002 Plasma Concentration

To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion

Interventionmicrograms per millileter (Mean)
Maximum Dose Level 3.33 g/24h65.6
Maximum Dose Level 6.65 g/24h32.2
Maximum Dose Level 10 g/24h33.4
Maximum Dose Level 20g/24h104.9

Neurological Function Measured by the Orientation Log (O-log)

The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days

Interventionunits on a scale (Mean)
Maximum Dose Level 3.33 g/24h23.8
Maximum Dose Level 6.65 g/24h24.0
Maximum Dose Level 10 g/24h24.0
Maximum Dose Level 20g/24h24.0

Neurological Function Measured by the West Haven Criteria (WHC) for Hepatic Encephalopathy

The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion

Interventionunits on a scale (Mean)
Maximum Dose Level 3.33 g/24h2.4
Maximum Dose Level 6.65 g/24h3.2
Maximum Dose Level 10 g/24h1.6
Maximum Dose Level 20g/24h1.8

Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability

To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Maximum Dose Level 3.33 g/24h0
Maximum Dose Level 6.65 g/24h0
Maximum Dose Level 10 g/24h0
Maximum Dose Level 20g/24h0

Reviews

3 reviews available for acetaminophen and Hepatolenticular Degeneration

ArticleYear
Acute Liver Failure.
    Seminars in respiratory and critical care medicine, 2018, Volume: 39, Issue:5

    Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Critical Care; Drug Overdose; Hepatitis, Auto

2018
Etiologies of acute liver failure.
    Seminars in liver disease, 2008, Volume: 28, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Budd-Chiari Syndrome; Drug-Related Side Effects and Adverse

2008
ABC of diseases of liver, pancreas, and biliary system. Other causes of parenchymal liver disease.
    BMJ (Clinical research ed.), 2001, Feb-03, Volume: 322, Issue:7281

    Topics: Acetaminophen; Cholangitis, Sclerosing; Cholestasis; Drug Hypersensitivity; Hemochromatosis; Hepatit

2001

Other Studies

3 other studies available for acetaminophen and Hepatolenticular Degeneration

ArticleYear
Transplant-free Survival in Chronic Liver Disease Presenting as Acute Liver Failure in Childhood.
    Transplantation, 2019, Volume: 103, Issue:3

    Topics: Acetaminophen; Child; Child, Preschool; End Stage Liver Disease; Female; Graft Survival; Hepatic Enc

2019
Case 2-2017. An 18-Year-Old Woman with Acute Liver Failure.
    The New England journal of medicine, 2017, 01-19, Volume: 376, Issue:3

    Topics: Abdomen; Acetaminophen; Adolescent; Diagnosis, Differential; Female; Hepatolenticular Degeneration;

2017
Liver transplant and obstetrics.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2004, Volume: 24, Issue:7

    Topics: Acetaminophen; Adult; Congenital Abnormalities; Drug Overdose; Female; Hepatolenticular Degeneration

2004